Search for drugs:

VORAPAXAR


DIR Classification


Classification:Ambiguous
Severity Score:1.0

Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF

  • CLINICAL PHARMACOLOGY
  • Pharmacodynamics
  • Evaluation of Vorapaxar on QTc Interval
  • The effect of vorapaxar on the QTc interval was evaluated in a thorough QT study and in other studies. Vorapaxar had no effect on the QTc interval at single doses up to 48 times the recommended dose.

Postmarketing Surveillance

Contingency Table:

Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
0
38381587

Odds Ratio = N/A

Drug Property Information



ATC Code(s):
  • B01AC26 - vorapaxar
    • B01AC2 -
    • B01AC - Platelet aggregation inhibitors excl. heparin
    • B01A - ANTITHROMBOTIC AGENTS
    • B01 - ANTITHROMBOTIC AGENTS
    • B - BLOOD AND BLOOD FORMING ORGANS
Active Ingredient:vorapaxar sulfate
Active Ingredient UNII:IN66038E6C
Drugbank ID:DB09030
PubChem Compound:10077130
CTD ID: C530299
PharmGKB:
CAS Number:618385-01-6
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
  • 2.08 mg/day B01AC26
Chemical Structure:
SMILE Code:
[H][C@@]12C[C@]3([H])C[C@@H](CC[C@@]3([H])[C@H](\C=C\C3=CC=C(C=N3)C3=CC(F)=CC=C3)[C@]1([H])[C@@H](C)OC2=O)NC(=O)OCC

Reference

1: Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trial.

[Kosoglou Teddy,Hunt Thomas L,Xuan Fengjuan,Kumar Bharath,Statkevich Paul,Hanson Mary E,Cutler David L]
Clin Pharmacol Drug Dev,2014 Jan;3(1):18-24. PMID: 27128226

Disclaimer:

The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.

Any mention of commercial products is for clarification and not intended as endorsement.